7/7/2020, 3:29 PM (Source: TeleTrader)
more TeleTrader news

GSK, Medicago to work together on virus vaccine

GlaxoSmithKline plc (GSK) and biotechnology company Medicago Inc. revealed on Tuesday a plan to jointly "develop and evaluate a COVID-19 candidate vaccine combining Medicago's recombinant Coronavirus Virus-Like Particles (CoVLP) with GSK's pandemic adjuvant system."

According to the companies' statement, the project is expected to result in a COVID-19 vaccine becoming available in the first half of 2021. The first phase of clinical trials is scheduled to begin in mid-July.

"This agreement paves the way for an innovative vaccine option combining a scalable plant-based antigen technology with an adjuvant which has pandemic dose sparing capability. [...] We strongly believe that multiple vaccines are needed, including post-pandemic vaccines," GSK Vaccines Chief Medical Officer Dr. Thomas Breuer said in the press release.

Breaking the News / MS